16(R)-HETE (BioCAD00000001988)
Metabolite Card
Formula: C20H32O3 (320.2351)
SMILES: CCCC[C@@H](O)\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O
Synonyms [en]
16(R)-HETE; 16R-HETE; (5Z,8Z,11Z,14Z)-(16R)-16-Hydroxyicosa-5,8,11,14-tetraenoic acid; 16R-Hydroxy-5Z,8Z,11Z,14Z-eicosatetraenoic acid; (5Z,8Z,11Z,14Z)-(16R)-16-Hydroxyeicosa-5,8,11,14-tetraenoic acid; (5Z,8Z,11Z,14Z,16R)-16-hydroxyicosa-5,8,11,14-tetraenoic acid
Last reviewed on 2024-06-28.
Cite this Page
16(R)-HETE. 数据之源，洞见之始. SMRUCC genomics institute, a synthetic life researcher from China.
https://biocad_registry.innovation.ac.cn/s/(-)-arctiin
(retrieved
2026-01-03) (CAD Registry RN: BioCAD00000001988). Licensed
under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).
Note
16(R)-HETE is a metabolite of arachidonic acid, metabolized by the enzyme Cytochrome P450, family 2, subfamily C [EC:1.14.13.80 1.14.13.48 1.14.13.49]. 16(R)-HETE is an endogenous lipidic inhibitor of human neutrophil inhibitor of adhesion and aggregation activity. Human polymorphonuclear leukocytes (PMNs) produce 16(R)-HETE that modulates their function. HETEs have different biological properties based on sites of production and can be stored in tissue lipids and released in response to hormonal stimuli. Eicosanoids generated during the actions of growth factors and vasoconstrictors can modulate disease processes by affecting vascular homeostasis, inflammation, cellular growth, apoptosis and oxidant stress. In lung, the presence of these eicosanoids in the pulmonary vasculature and airways, including effects on pulmonary vascular and bronchial smooth muscle tone and airway epithelial ion transport. (PMID: 16258232, 14626496, 12681244, 11123211, 14552765, 11126912).
DBLinks
- CAS Registry Number: 183509-22-0
- PubChem CID: 9548884
- ChEBI: 34162
- HMDB: HMDB0004680
- LipidMaps: LMFA03060069
- KEGG: C14778
- BioCyc:
- NCBI MeSH:
- Wikipedia:
Other DBLinks
- CAS Registry Number: 183509-22-0
- PubChem: 9548884
- ChEBI: ChEBI:34162
- HMDB: HMDB0004680
- LipidMaps: LMFA03060069
- KEGG: C14778
- RefMet: RM0158224
- Metlin: METLIN_36321
- Coconut NaturalProduct: CNP0083474.1
- Coconut NaturalProduct: CNP0083474.3
- Coconut NaturalProduct: CNP0220963.1
Class / Ontology
- WishartLab ClassyFire: [Eicosanoids] Eicosanoids
- RefMet: [HETE] HETE
- LipidMaps: [Hydroxy/hydroperoxyeicosatetraenoic acids [FA0306]] Hydroxy/hydroperoxyeicosatetraenoic acids [FA0306]
- ChEBI: [CHEBI:34162] 16(R)-HETE
- Coconut NaturalProduct: [Hydroxy-hydroperoxyeicosatetraenoic acids] Hydroxy-hydroperoxyeicosatetraenoic acids
| ID | EC Number | Name |
|---|---|---|
| KEGG:R07054 | 1.14.14.1 | C00219 + C00007 + C00005 + C00080<=>C14778 + C00006 + C00001 |
Taxonomy Source
Pathway Synthetic
| pathway id | name |
|---|---|
| PathBank:SMP0120730 | Leukotriene C4 Synthesis Deficiency |
| PathBank:SMP0000083 | Acetylsalicylic Acid Action Pathway |
| PathBank:SMP0000087 | Rofecoxib Action Pathway |
| PathBank:SMP0000094 | Sulindac Action Pathway |
| PathBank:SMP0000104 | Indomethacin Action Pathway |
| PathBank:SMP0000120 | Naproxen Action Pathway |
| PathBank:SMP0000106 | Meloxicam Action Pathway |
| PathBank:SMP0000693 | Antrafenine Action Pathway |
| PathBank:SMP0000697 | Flurbiprofen Action Pathway |
| PathBank:SMP0000701 | Phenylbutazone Action Pathway |
| PathBank:SMP0000705 | Tiaprofenic Acid Action Pathway |
| PathBank:SMP0000709 | Salicylic Acid Action Pathway |
| PathBank:SMP0000075 | Arachidonic Acid Metabolism |
| PathBank:SMP0000086 | Ibuprofen Action Pathway |
| PathBank:SMP0000093 | Diclofenac Action Pathway |
| PathBank:SMP0000098 | Ketorolac Action Pathway |
| PathBank:SMP0000102 | Bromfenac Action Pathway |
| PathBank:SMP0000114 | Nabumetone Action Pathway |
| PathBank:SMP0000692 | Antipyrine Action Pathway |
| PathBank:SMP0000696 | Fenoprofen Action Pathway |